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Abstract 
 
Preliminary studies have suggested that GABAA receptors, and perhaps especially the 
GABAA α5 subtype, are deficient in autism spectrum disorder (ASD). However, prior 
studies were confounded by medication effects, and did not compare findings across 
species. Hence, we measured both total GABAA and GABAA α5 receptor availability in 
two Positron Emission Tomography (PET) studies using the tracers [11C]flumazenil (15 
ASD adults, 15 controls) and [11C]Ro15-4513 (12 ASD adults, 16 controls) respectively. 
All participants were medication-free. We also performed autoradiography, using the 
same tracers, in three mouse ASD models: Cntnap2 k/o, Shank3 k/o and 16p11.2 
deletion. We found no significant differences in GABAA or GABAAα5 receptor 
availability in any brain region in ASD. There were likewise no differences in any of the 
mouse models. However, humans with ASD did display altered performance on a GABA-
sensitive perceptual task. GABAA receptor availability is normal in adults with ASD, 
though GABA signaling may yet be functionally impaired.
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Introduction 
 
Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterised by 
impairments in social communication and interaction, alongside restricted and repetitive 
behaviours and interests.(1-3) The prevalence of ASD is estimated at 0.6-1.5%, with each 
case of the disorder being associated with projected lifetime care and loss of productivity 
costs of around $1.5 million.(4, 5) Currently, there are no specific “disease-modifying” 
pharmacological treatments for ASD, and drug discovery has been hampered by poor 
understanding of the pathophysiology of the condition. 
 
There is, however, increasing evidence for an excess of brain excitatory glutamate and/or a 
deficit in inhibitory gamma-aminobutyric acid (GABA) in ASD.(6-8) For instance, reduced 
expression of the GABA synthesis enzyme glutamic acid decarboxylase (GAD) has been 
observed in ASD brains post mortem.(9) In vivo, alterations in glutamate and glutamine have 
been reported in the cortex and basal ganglia of children, and in the basal ganglia of adults 
with ASD, as measured with proton magnetic resonance spectroscopy, [1H]MRS.(10-13) 
Reductions in GABA concentration have also been reported by several [1H]MRS studies of 
ASD children.(14, 15) However, a limitation of [1H]MRS is that it is unable to determine 
neurotransmitter receptor density.  
 
Alterations in the expression of GABA receptors, of which GABAA is the most prevalent 
type in the brain,(16-18) may be a key contributor to the excitatory/inhibitory imbalance in 
ASD. Reductions in the density of GABAA receptors have been reported in post-mortem 
studies of ASD in the hippocampus(19) and cingulate cortex.(20, 21) Although these studies 
were valuable first steps, their sample sizes were small, and they included individuals taking 
medications such as anticonvulsants which might alter GABAA expression, leaving it unclear 
whether their findings could be replicated by in vivo studies. 
 
Two in vivo studies have reported reductions of GABAA in ASD. Using [123I]iomazenil 
Single Photon Emission Computed Tomography (SPECT), Mori et al. reported significantly 
decreased GABAA availability in children with ASD.(22) However, this study included 
children with epilepsy and intellectual disability, and some participants were on 
anticonvulsants. Hence, it remained unclear whether it was ASD, or a confounding factor, 
which was associated with reduced GABAA receptors. Therefore, we subsequently carried 
out a pilot study(23) using Positron Emission Tomography (PET) with the tracer [11C]Ro15-
4513. Our participants were medication-free adult males with ASD and no epilepsy or 
intellectual disability, and controls. We found significantly reduced availability of the 
GABAA α5 subtype in ASD, with no alterations in the non-α5 subunits. However, this 
preliminary study was small, including 3 adults with ASD and 3 controls. Also, it did not 
clarify whether it is overall GABAA, or GABAA α5 specifically, that is altered in ASD. Hence 
we designed the present investigation to replicate and extend prior in vivo GABAA studies in 
a new and larger sample; the data from the pilot were not included in the present analysis. 
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A further motivation for the present study was ‘translational’. If the GABAA receptor is 
abnormal in ASD, it might provide a drug target. However, to provide a rational screen for 
new treatments, drug development would require animal models that recapitulate any 
GABAA alterations seen in humans. Altered GABAA expression has indeed been observed in 
rodent models of ASD-associated syndromic disorders, including Fragile X syndrome(24) 
and Rett's syndrome.(25, 26). However, approximately 90% of ASD cases are 
nonsyndromic,(27) so we set out to examine whether GABAA alterations are seen in animal 
models of nonsyndromic ASD. 
 
A final motivation for this study was to investigate GABAergic function in ASD adults. This 
was based on our reasoning that the functional integrity of GABAergic circuits might be 
abnormal in ASD even if GABAA receptors are unchanged. If so, this would suggest the 
presence of an abnormality elsewhere in the GABAergic system. 
 
Hence, our aims in the present investigation were to: a) confirm whether GABAA expression 
is altered in humans with nonsyndromic ASD; b) determine whether any putative changes are 
specific to the GABAA α5 subtype; c) discover which, if any, of our chosen rodent models 
display the same pattern of GABAA alterations seen in humans; and d) determine whether 
ASD is associated with functional impairment in GABAergic circuits using a 'proxy measure' 
of GABAergic function in humans. 
 
We therefore conducted the first integrated, translational, investigation of GABAA across 
both humans and mouse models of ASD. In humans, we carried out two PET studies in two 
experimental centres: in Stockholm using [11C]flumazenil(28) and in London using 
[11C]Ro15-4513.(29, 30) We chose [11C]flumazenil as a non-selective tracer as it binds α1, 
α2, α3 and α5,(31) covering the vast majority of GABAA receptors in the brain(32) with 
approximately equal affinity. [11C]Ro15-4513 was chosen for its 10-fold higher affinity for 
α5 over the other subtypes α1-4 and α6, at which it has approximately equal affinity.(31) The 
α5 subtype of the GABAA receptor has been especially linked to ASD.(23, 33, 34) Both PET 
studies formed part of the Innovative Medicines Initiative (IMI) European Autism 
Interventions Multicenter Study (EU-AIMS) project.(35) 
 
In mice, we selected three commonly used, etiologically diverse ASD models that represent a 
range of genetic risk factors for ASD in humans: Cntnap2(36) knockout mice, Shank3(37) 
knockout mice, and mice carrying a genetic deletion equivalent to human chromosome 
16p11.2 deletion, which is one of the most common copy-number variants (CNVs) found in 
ASD.(38) These models were selected as well-established and well-characterized ASD 
models. Employing the same radiotracers used for PET, we performed autoradiography for 
quantification of GABAA receptors in rodent brains. Autoradiography was used rather than 
small animal PET because it provides better spatial resolution, and because PET would have 
required the animals to be anaesthetized during scanning, which could impact on GABA. 
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Finally, to investigate the functional balance between excitatory/inhibitory neurotransmission 
using a visual psychophysics task, we used the paradoxical motion perception task (PMP), 
known to be a proxy measure of GABA functionality.(39, 40)
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Results 
  
 PET studies 
 
  [11C]flumazenil: No differences in GABAA receptor availability 
 
There was no evidence of group differences in estimated [11C]flumazenil binding potential in 
the whole brain (independent samples t-test: t(28)=1.304, p=0.203, d=0.476), in brain grey 
matter (t(28)=1.283, p=0.210, d=0.468), or in any of the 13 specific brain regions we 
examined (all p>0.156). This suggests that there were no differences in GABAA receptor 
availability in ASD. See Figures 1, 2, and 3a. There were no significant differences in 
[11C]flumazenil tracer dosing between the two groups (see Table S1). 
 
Sensitivity analyses including correction for partial volume effects, inclusion of male 
participants only, and exploratory voxel-wise analysis did not affect the results (see 
Supplementary Material.) 
 
There were no correlations between grey matter GABAA receptor availability and 
performance on any of a battery of ASD-related cognitive and social-cognitive tasks 
including the Embedded Figure Test,(41) Reading the Mind in the Eyes Test,(42) and the 
Faux Pas test.(43) See the Supplementary Methods & Results for details. There was no 
difference between the typically developing control and the ASD groups in terms of age or 
full-scale IQ. See Table 1. 
 
[11C]Ro15-4513: No differences in GABAA non-α5 or α5 receptor availability 
 
A primary analysis showed no group differences in total specific [11C]Ro15-4513 binding, 
from 2TCM, in the whole brain (independent samples t-test: t(25)=-1.392, p=0.176, 
d=0.574), in brain grey matter (t(25)=-1.516, p=0.142, d=0.614), or in 11 of the 13 specific 
brain regions we examined (all p>0.1) In the cerebellum and the thalamic regions, nominally 
significant increases in binding were observed in the ASD group (t(25)=-2.132, p=0.043, 
d=0.820 and t(25)=-2.513, p=0.019, d=0.974 respectively), but these did not survive 
Bonferroni correction for multiple comparisons. There were no significant differences in 
[11C]Ro15-4513 tracer dosing between the two groups (see Table S1). 
 
In a secondary analysis of the [11C]Ro15-4513 data, we used nonlinear spectral analysis 
(NLSA)(23) to distinguish non-α5 and α5 subtype availability. This confirmed that there 
were no differences in either non-α5 (t(24)=-0.163, p=0.872, d=0.064) or α5 (t(23)=-0.805, 
p=0.429, d=0.322) subtype receptor availabilities in adults with ASD in the whole brain. 
Across the brain areas, there were no significant regional differences in either non-α5 or α5 
availability in any brain area, except for increased α5 availability in the insula in ASD 
(t(18)=-2.345, p=0.029, d=1.063) which did not survive correction for multiple comparisons. 
See Figures 1, 3b, and 4. In particular, we did not observe any differences in α5 availability 
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in the hippocampus or amygdala regions (all p>0.3), i.e. in those areas in which significant 
differences were detected in our previous pilot study.(23) Finally, there was no difference 
between the typically developing control and the ASD groups in terms of age or full-scale IQ. 
See Table 1. 
  
Quantitative autoradiography findings 
 
GABAA autoradiography was performed in three mouse models of ASD: Cntnap2 knockout 
mice, Shank3 knockout mice, and 16p11.2 deletion. Six brain regions were examined 
bilaterally: the frontal cortex, cingulate cortex, caudate/putamen, dorsal hippocampus, 
cerebellum, and amygdala. We observed no significant differences in the specific binding of 
either [3H]flumazenil or [3H]Ro15-4513 in any model or region compared to the control (wild 
type) animals (all p>0.05). See Figure 5. For left and right amygdala results, see Figure S1. 
 
Evidence of a functional GABAergic deficit (motion perception task) 
 
The paradoxical motion perception task (PMP) was used as a proxy measure of GABA 
function in the visual cortex. We first verified that the paradoxical motion perception 
effect(39) was present in the healthy controls. The effect was significant: one-sample t-test: 
t(17)=3.99, p<0.001, mean PMP ratio=1.844 (95% CI: 1.398-2.290 where 1 is no effect, 
demonstrating successful implementation of the task. 
 
The magnitude of the contrast-induced motion perceptual impairment ratio was reduced in 
the ASD group compared to the controls. (Independent samples t-test with Welch-
Satterthwaite correction for unequal variances: t(28)=2.487, p=0.022, d=0.921 two-tailed. 
Bootstrapped t-test: p=0.028 with 10,000 samples) See Figure 6. Individuals with an ASD 
were less impaired by the high contrast stimuli than the controls. This group difference was 
not accounted for by low-level differences in the ability to detect motion, because there were 
no group differences in perceptual threshold in either of the two control conditions (both 
p>0.4). Furthermore, the paradoxical effect of contrast on motion perception was not 
correlated with age (n=30, r=0.026, p=0.892) or IQ (n=29, r=0.243, p=0.203). 
 
Therefore, adults with ASD have a selective enhancement of motion perception under 
conditions of high contrast, a pattern of results considered indicative of a GABAergic 
signalling deficit. 
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Discussion 
 
We conducted a multisite, translational molecular imaging study of GABAA receptors in 
adults with ASD and rodent models. Our objective was to test in vivo the hypothesis that 
ASD is associated with reduced amounts of GABAA receptors. We found no direct evidence 
in support of this hypothesis. Our results show that unmedicated adults with idiopathic ASD, 
and no intellectual disability, have normal availability of both total GABAA receptors, and of 
the key GABAA α5 receptor subtype. There were no correlations between GABAA receptor 
availability and social cognitive task performance. Furthermore, strengthening our confidence 
in these findings, GABAA availability was not altered in three common mouse models of 
ASD, namely Cntnap2 knockout, Shank3 knockout, and 16p11.2 deletion. Nonetheless, a 
visual perceptual proxy measure of cortical GABAergic signalling revealed evidence 
consistent with a functional GABA deficit in the ASD group in the [11C]Ro15-4513 human 
study. 
 
This is the first large in vivo study of GABAA receptor availability in unmedicated adults 
with ASD. Our results contrast with reports of reduced GABAA availability in in children 
with ASD using SPECT.(22) The difference between those results and ours may indicate an 
age-specific alteration in GABAA availability in ASD, but other methodological differences 
should also be considered. For instance, in the SPECT study the control group consisted of 
partial epilepsy patients, the majority of whom were medicated with anticonvulsants. In 
contrast, we recruited medication-free ASD and typically-developing control individuals in 
order to avoid any medical or medication confounds. The null findings in the present PET 
results also stands in contrast to our own pilot PET study(23) that reported reduced GABAA 
α5 subtype availability in 3 ASD adults compared to 3 matched controls. It is possible that 
our prior finding was a Type I error. 
 
While our results suggest that GABAA receptor availability is not altered in ASD, other 
interpretations of our data should be considered. One possibility is that our studies lacked 
statistical power to detect any differences in GABAA. Both of our PET studies were powered 
at 80% to detect an effect size typical of PET studies e.g. (44). A second possible explanation 
for our negative result is that the PET tracers we used were insensitive, yet we consider this 
unlikely as both [11C]flumazenil and [11C]Ro15-4513 have been used successfully to detect 
group differences in GABAA receptor availability in other neuropsychiatric disorders,(44, 45) 
and in healthy controls differing in behavioral phenotype.(46) 
 
While we found no detectable differences in GABAA using [11C]flumazenil and [11C]Ro15-
4513 PET in man, we did observe a significant alteration in performance on a visual 
perception task which has been proposed to index cortical GABAergic function.(39, 40) A 
number of other groups have reported similar findings in individuals with ASD.(47) This 
raises the possibility that the GABA system may be dysregulated in ASD, despite intact 
GABAA receptor expression. For instance, it is possible that the synthesis and/or release of 
GABA is downregulated in ASD, leading to impaired GABAergic signaling.(48) Moreover 
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GABAA receptors might be present in normal number – but be abnormally localized on 
postsynaptic neurons, affecting their functionality, as has been observed e.g. in epilepsy.(49) 
Future research could explore these possibilities.  
 
Our rodent autoradiography results reflect our human findings. GABAA was not altered in 
any of the three commonly used mouse genetic models of ASD we examined. This is the first 
study to examine GABAA in any of these three models, but alterations in GABAA might have 
been expected based on the functions of the affected genes. Cntnap2 is a cell adhesion 
molecule belonging to neurexin family(50) and involved in dendritic arborization and spine 
development. While involved in excitatory synapse function, Cntnap2 k/o also reduces 
inhibitory (GABAergic) transmission.(50) Shank3 is another synaptic protein that plays a role 
in signalling to presynaptic buttons through the neuroligin-neurexin transsynaptic signalling 
complex,(51) and it has been linked to inhibitory signalling.(52, 53) Finally, 16p11.2 deletion 
is a chromosomal microdeletion associated with ASD in humans.(54) The gene(s) responsible 
for the phenotype are unclear, but synaptic genes may be key. (54) In contrast to our results, 
increased Ro15-4513 (but not muscimol) binding was recently reported in the left amygdala 
of valproate-exposed (VPA) rats.(55) Our study differed from that in a number of ways: we 
used mice not rats, we examined genetic rather than valproate-induced ASD models, and our 
animals were older, at 12 weeks of age vs. 7 weeks. Therefore our finding of no alterations in 
GABAA tracer binding in any of the three models we examined does not rule out the 
possibility that other models might show such differences. We suggest, however, that our 
data at least establish that GABAA alterations are not a shared phenotype across all ASD 
models. 
 
Limitations of our research include the fact that  due to prohibitions on exposing children to 
research PET, we were only able to recruit adults, so we are unable to exclude the possibility 
of abnormalities in GABAA in children with ASD. Similarly, we were only able to recruit 
males in the [11C]Ro15-4513 study, because of British regulations restricting the exposure of 
women of reproductive age to radiation for research. This limits the generalizability of our 
findings, although the majority of ASD cases are males.(3) Our patient population was also 
relatively high-functioning and free of medical comorbidities, with above average mean IQ 
scores and no epilepsy. While this represents a strength of the study in terms of avoidance of 
confounds, it also limits generalizability. It is possible that GABAA receptor abnormalities 
are present in ASD individuals with epilepsy and/or intellectual disability. Testing this 
hypothesis using PET, however, could raise ethical issues over exposure to radiation in a 
vulnerable group who may be less able to give informed consent. Finally, we were able to 
selectively quantify GABAA α5 subtype but could not perform the same procedure for other 
subtypes such as α2 and α3, owing to a lack of suitable tracers. 
 
A further limitation of our study  is that we included only a limited range (three) of mouse 
genetic models for autoradiography. GABAA alterations in other models cannot be ruled out. 
It could furthermore be questioned whether the models we used are valid models for the 
phenotype of our human ASD participants. For instance, many humans with Cntnap2, 
Page 10 of 28 22nd October 2017 
 
 
Shank3, and 16p11.2 mutations have epilepsy (see (56)), whereas we excluded people with 
epilepsy. However, we do not think that this is a key limitation, given that we report no 
difference in GABAA in any of the models. Had we observed alterations in rodent GABAA, it 
would have been difficult to exclude the possibility that they were correlates of epilepsy 
rather than of ASD per se, but the same concern does not apply to our null results. A final 
limitation of both PET and autoradiography is that they are only able to quantify the density 
of GABAA receptors and not their functionality, for which purposes other methods such as 
electrophysiology would be required.  
 
In conclusion, we used PET and autoradiography to investigate the inhibitory GABA system 
in adults with an ASD and mouse models of ASD. Our objective was to test a major 
prediction of the excitatory:inhibitory imbalance hypothesis, namely that GABAA receptor 
availability is reduced in this disorder. We found normal availability of total GABAA, 
receptors, and of the GABAA non-α5 and α5 subtypes, in humans with ASD, and we 
recapitulated these findings in three diverse mouse models of ASD, although we did find 
behavioral differences consistent with a functional GABAergic deficit in humans. 
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Materials and Methods 
 
 Study Design 
 
We carried out two human PET studies at two PET centers: Stockholm (Sweden) and London 
(UK). Each study was designed to compare GABAA receptor availability in adults with ASD 
to adult controls. The two studies were intended to study a different aspect of  GABAA to 
provide convergent evidence. In Stockholm, we measured brain GABAA receptor binding 
using PET with the non-selective tracer [11C]flumazenil (also known as [11C]Ro15-1788).(57) 
In London, we measured GABAA non-α5 and α5 receptor availability using PET with the α5-
selective tracer [11C]Ro15-4513. We included 15 (11 males) typically developing adult 
controls vs. 15 (11 males) ASD participants in the [11C]flumazenil study in Stockholm, and a 
separate group of 16 (all males) typically developing controls vs. 12 (all males) ASD in the 
[11C]Ro15-4513 study in London. 
 
We also performed a quantitative autoradiography experiment to estimate GABAA receptor 
density in brain slices from three mutant strains commonly used as ASD models, namely 
Cntnap2 knockout, Shank3 knockout, and 16p11.2df (deletion) (Jackson Laboratories, stock 
#013128). Control mice included wild type (WT) littermates. In all three models, there was 
an N=7-8 for the wild type mice and an N=8 for the knockouts. Randomization was not used 
as this was an observational study. PET and autoradiography image analysis and 
quantification was performed by individuals blind to group status. 
 
.  
 
 Human PET: Participants and Recruitment 
 
In Stockholm, the ASD participants were recruited via the Stockholm County healthcare 
services. In London the ASD participants were recruited from the Behavioural Genetics 
Clinic (BGC) at the Maudsley Hospital, a national referral service for the diagnosis of 
neurodevelopmental disorders. In each center, typically developing controls were recruited 
via local advertisements. 
 
All participants were required to meet the following criteria: 1) Full Scale IQ of 70+ 2) Not 
currently taking any psychoactive medication, and no history of psychoactive medication use 
within at least the past six weeks. 3) No history of epilepsy, head injury or trauma with 
unconsciousness of more than five minutes, brain disease or infection, or serious medical 
illness by self-report. 4) No history of bipolar disorder, schizophrenia, drug or alcohol 
dependency or other DSM Axis I disorder 5) MRI safe 6) Physically in good health and 
suitable for PET according a brief physical examination. 7) For female participants, not 
pregnant. 8) Aged 18+. 
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In addition, participants in the ASD group were required to meet ICD-10 criteria for autism, 
and to have received a clinical diagnosis of ASD by an experienced psychiatrist involved in 
the study. Diagnoses were informed by the Autism Diagnostic Observation Schedule (ADOS) 
in all participants and where possible the Autism Diagnostic Interview – Revised (ADI-R) 
(10/12 ASD participants in the London sample.) 
For details on past use of psychoactive medication, and a measure of functional impairment 
(employment status), see Table S2. 
For the [11C]flumazenil study in Stockholm, IQ was estimated from the Vocabulary and 
Matrix Reasoning subscales of the Wechsler Abbreviated Intelligence Scale IV (WAIS-IV), 
administered in Swedish.(58) For the [11C]Ro15-4513 study in London, IQ was assessed 
using the English version of the Wechsler Abbreviated Scale of Intelligence (WASI) with 
four subscales: Vocabulary, Similarities, Block Design and Matrix Reasoning. 
 
[11C]flumazenil and [11C]Ro15-4513 human PET data acquisition and processing 
 
The following is a summary of the methods used in the two human PET studies. For more 
details, please see the Supplementary Material. 
 
[11C]flumazenil was prepared as previously described,(59) and injected in the antecubital vein 
as a 10 second bolus. [11C]flumazenil PET was performed on a Siemens ECAT Exact HR 47 
(CTI/Siemens, Knoxville, TN) run in 3D mode with Dual Energy Windows scatter 
correction. A 10 minute transmission scan was performed to correct for attenuation and 
scatter. PET data was collected in a dynamic scan lasting 63 minutes and binned into 26 time 
frames. PET images were reconstructed using filtered backprojection and corrected for head 
motion using a frame to first frames approach. T1 weighted MR images were coregistered to 
PET using SPM5. MRIs were segmented and regions of interest (ROIs) were delineated using 
Freesurfer.(60) Regional binding potential values (BPND) were calculated using the 
Simplified Reference Tissue Model (SRTM) with pons acting as reference region. 
 
[11C]Ro15-4513 was synthesised as previously described and injected in the dominant 
antecubital vein as a 15 second bolus. PET emission data was collected in 3D mode for 90 
min. During the PET acquisition, arterial blood data were sampled via the radial artery using 
a combined automatic-manual approach. Dynamic PET data were corrected for inter-frame 
motion and aligned with the individual’s structural T1 MR image. An atlas was coregistered 
on each subject’s image space and a subset of regions including amygdala, hippocampus and 
nucleus accumbens, were considered. Two kinetic methods with metabolite-corrected plasma 
input functions were applied for the data analysis: (i) a two-tissue compartmental model (ii) a 
spectral-based quantification method, non-linear spectral analysis (NLSA) to separate GABA 
non-α5 and α5-related components (V1 and V5, respectively) from the total tracer uptake.(34) 
 
 Rodent autoradiography: overview and animal models 
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We performed quantitative autoradiography to estimate GABAA receptor density in brain 
slices from Cntnap2 knockout (Cntanp2 -/-) (provided by Michael Saxe, Roche), Shank3 
knockout (Shank3 -/-) (Michael Saxe, Roche) and 16p11.2df (deletion) (Jackson 
Laboratories, stock #013128). Control mice included wild type (WT) littermates. Mice were 
killed by decapitation, their brains rapidly removed and frozen in cooled isopentane. In order 
to approximate the patient demographics in the human ASD PET study as closely as possible, 
we used mature adult (12 weeks of age), male mice in all cases. In all three groups, there was 
an N=7-8 for the wild type mice and an N=8 for the knockouts.  
 
 Rodent autoradiography: protocol 
 
Please see the Supplementary Material. 
 
 GABA visual task 
 
In order to complement our PET measures of GABAA receptor availability, we chose to 
investigate the functional balance between E:I neurotransmission using the paradoxical 
motion perception (PMP) task as a proxy measure. In this paradigm, high visual contrast 
normatively impairs perception of the direction of motion of sine wave grating stimuli, i.e. 
paradoxically, lower contrast stimuli are easier to perceive. This effect is believed(39) to 
reflect GABAergic lateral inhibition in the visual cortex.  
 
 GABA visual task: Method 
 
During the PMP task, participants view brief presentations of a drifting sine wave gratings of 
varying size (small vs. large) and contrast (bright vs. faint). The task is to indicate the 
direction of motion. PMP stimuli were greyscale vertical sine-wave gratings masked with a 
Gaussian centred on the middle of the screen. Gratings had a spatial frequency of 1 
cycle/degree of visual angle at the viewing distance of 50 cm. Each grating drifted at 2 
degrees/second either left or right (randomly determined on each trial.) Stimulus size, defined 
as the spatial SD of the Gaussian mask, was 0.35 degrees for the small and 2.50 degrees for 
large stimuli. The bright stimuli used the maximum contrast of 127 provided by the 
Presentation software while the dim stimuli used a contrast of 5, which was chosen in piloting 
as the lowest contrast that was clearly perceptible to all participants. 
 
There were 260 trials, 65 each of four trial types (small dim, small bright, large dim, large 
bright). Psychometric estimation was performed using a 2-up-1-down duration staircase. 
There were four staircases, one per stimulus type. Each staircase began at 250 milliseconds, 
with the step up (harder) at -14.1 milliseconds per 2 correct answers (i.e. the stimuli were 
made briefer), and step down (easier) was 18.2 milliseconds per 1 incorrect answer i.e. the 
stimuli were made longer. A failure to respond was counted as incorrect. Participants 
performed the task in a darkened room. 
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GABA visual task: Data Analysis 
 
In line with previous work, contrast impairment on motion perception is defined as the ratio 
between the estimated threshold (in milliseconds) for large-bright compared to large-faint 
stimuli. Trial-by-trial results were analysed using a custom Microsoft Excel macro to detect 
reversals. We calculated perceptual thresholds for each stimulus condition by taking the mean 
of all of the reversals, as this is the best estimator of the psychometric threshold in a forced-
choice staircase design.  
 
 Statistics 
 
For all analyses, α was set at 0.05 and two-tailed tests were used. For the [11C]flumazenil and 
[11C]Ro15-4513 PET studies, group differences in estimated receptor availability (BPnd and 
VT respectively) were compared using an independent sample t-tests for each of the defined 
brain regions separately. Results are reported as uncorrected p-values, with remarks 
indicating whether significant results would survive Bonferroni correction over the number of 
brain regions within each study. For the PMP task, the magnitude of the contrast-induced 
motion perceptual impairment ratio was compared between groups using an independent 
samples t-test with Welch-Satterthwaite correction for unequal variances. For the rodent 
autoradiography, non-specific binding was subtracted from the total binding to give the 
specific binding values, which were compared between wild-type and mutant mice using 
unpaired t-tests corrected for multiple comparisons using Sidak correction.  
 
 Ethics 
 
The [11C]flumazenil study was approved by the Ethics and Radiation safety committees of 
the Karolinska Hospital and was performed in accordance with the Helsinki Declaration. The 
[11C]Ro15-4513 PET experiment was approved by North London Research Ethics Committee 
3, reference 10/H0709/90, and by the Administration of Radioactive Substances Advisory 
Committee (ARSAC) certificate 630 / 3764 / 28579. The PMP task was approved by Essex 2 
National Research Ethics Committee (Reference 04-Q0102/26). 
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Figures 
 
 
 
Figure 1. Estimated group mean [11C]flumazenil SRTM BPnd and [11C]Ro15-4513 VT in 
typically developing control adult and ASD adult samples. PET images were normalized into 
MNI-152 standard space, and are displayed overlaid on MNI-152 2mm resolution template 
anatomical MRI images. [11C]flumazenil n=15 control/15 ASD; [11C]Ro15-4513 n=16 
control/12 ASD. VT was calculated using the Logan method.  
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Figure 2. Estimated [11C]flumazenil binding (mean estimated BPND) across the whole brain 
and in subdivisions (regions) of the brain in typically developing controls and ASD 
participants in the Stockholm sample. n=15 control/15 ASD. 
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Figure 3. Scatterplots illustrating (a) estimated mean grey matter flumazenil BPND (b) 
estimated mean grey matter [11C]Ro15-4513 VT for individual participants in the typically 
developing control and ASD adult groups. There were no evident outliers or subgroups with 
either tracer. 
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Figure 4. Estimated [11C]Ro15-4513 specific binding, derived from two compartmental 
model (2TCM) of PET data, showing mean estimated VT across the whole brain and in 
subdivisions (regions) of the brain in typically developing controls and ASD participants in 
the London sample. n=16 control/12 ASD 
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Figure 5. Mouse autoradiography results. A,B,C,D: examples of the brain levels used. E,G,I: 
[3H]flumazenil specific binding. F,H,J: [3H]Ro15-4513 specific binding. E,F: wild type (WT) 
vs. 16p11.2 deletion mice. G,H: WT vs. Cntnap2-/- mice. I,J: WT vs. Shank3-/- mice. Bars 
show group mean signal, normalized such that the mean signal in the WT group = 100%. 
Error bars show SEM. 
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Figure 6. Contrast-induced motion perceptual impairment ratio in each participant, with 
higher values indicating more impairment. Impairment is considered a proxy for  GABA-
mediated contrast inhibition in the visual cortex. 
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Tables 
 
 
Stockholm 
Flumazenil PET study 
 
 
London 
Ro15-4513 PET study 
Measure Control ASD 
P-value 
(t-test) 
Control ASD 
P-value 
(t-test) 
Number 
Male / Female 
11 / 4 15 / 0 NA 16 / 0 12 / 0 NA 
Age 33.0 ± 9.4  33.0 ± 9.1 1.000 29.8 ± 9.1 30.7 ± 8.8 0.684 
Full Scale 
IQ 
113.1 ± 15.4 106.9 ± 17.9 0.318 122.7 ± 24.5 116.0 ± 13.9 0.256 
ADI 
Social 
NA NA NA NA 15.5 ± 6.1 NA 
ADI 
Communication 
NA NA NA NA 12.1 ± 7.0 NA 
ADI 
Repetitive 
NA NA NA NA 4.5 ± 2.6 NA 
ADOS 
Social 
NA 7.5 ± 5.1 NA NA 7.7 ± 2.1 NA 
ADOS 
Communication 
NA 6.9 ± 3.2 NA NA 3.9 ± 1.8 NA 
 
Table 1. PET participant demographics and ASD clinical scores from the two experimental 
studies. Values are shown as Mean ± Standard Deviation. P-values are the outcome of 
independent sample t-tests testing for a difference in group means, within each study. Clinical 
scores are not available for typically developing control participants. ADI scores were not 
available for the Stockholm cohort. 
 
